|
gptkbp:instanceOf
|
gptkb:drug
histamine H2 receptor antagonist
|
|
gptkbp:approvalYear
|
1986
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A02BA03
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
injectable solution
|
|
gptkbp:bioavailability
|
40-45%
|
|
gptkbp:brand
|
gptkb:Pepcid
gptkb:Pepcid_AC
|
|
gptkbp:CASNumber
|
gptkb:76824-35-6
|
|
gptkbp:chemicalFormula
|
C8H15N7O2S3
|
|
gptkbp:contraindication
|
hypersensitivity to famotidine
|
|
gptkbp:developedBy
|
gptkb:Yamanouchi_Pharmaceutical
|
|
gptkbp:discoveredIn
|
1979
|
|
gptkbp:drugClass
|
gptkb:H2_blocker
|
|
gptkbp:eliminationHalfLife
|
2.5-3.5 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
famotidine
|
|
gptkbp:interactsWith
|
gptkb:ketoconazole
gptkb:probenecid
gptkb:atazanavir
antacids
|
|
gptkbp:legalStatus
|
prescription
over-the-counter (in some countries)
|
|
gptkbp:marketedAs
|
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:mechanismOfAction
|
blocks H2 receptors in stomach
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
337.43 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
15-20%
|
|
gptkbp:reduces
|
gastric acid secretion
|
|
gptkbp:relatedTo
|
gptkb:ranitidine
gptkb:nizatidine
cimetidine
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
constipation
dizziness
fatigue
headache
|
|
gptkbp:usedFor
|
treatment of peptic ulcer disease
treatment of heartburn
treatment of Zollinger-Ellison syndrome
treatment of gastroesophageal reflux disease
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Pepcid
|
|
gptkbp:bfsLayer
|
5
|